Loading provider…
Loading provider…
Hematology (Internal Medicine) Physician in Minneapolis, MN
NPI: 1730440140Primary Practice Location
ABBOTT NORTHWESTERN HOSPITAL
800 E 28th St, Minneapolis, MN
Primary Employer
Allina Health Cancer Institute - Minneapolis
allinahealth.org
HQ Phone
Get M.D. Fiona's Phone Numberphone_androidMobile
Get M.D. Fiona's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 34 | 167 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 30 | 52 |
| 3 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 29 | 33 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 22 | 61 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 20 | 48 |
Encapsulated relapsed FLT3+AML (myeloid sarcoma) and Hürthle cell adenoma presenting in composite: Unlikely partners.
Authors: Celalettin Ustun, Zuzan Cayci
Publication Date: 2016-12
Effect of Keratinocyte Growth Factor on Hospital Readmission and Regimen-Related Toxicities after Autologous Hematopoietic Cell Transplantation for Lymphoma.
Authors: Najla El Jurdi, Joseph Maakaron, Murali Janakiram, Armin Rashidi, Veronika Bachanova, Erica Warlick, Mukta Arora, Daniel Weisdorf
Publication Date: 2020-09-23
Authors: Najla El Jurdi, Joseph Maakaron, Mark Juckett, Mukta Arora, Daniel Weisdorf
Journal: Transplant Cell Ther
Publication Date: 2024-06-03
Lead Sponsor: Imugene Limited
Intervention / Treatment: DRUG: Bendamustine, DRUG: Cyclophosphamide, DRUG: Fludarabine, BIOLOGICAL: Azer-cel, DRUG: IL-2
Lead Sponsor: AbbVie
Intervention / Treatment: DRUG: ABBV-319